These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 23259845)

  • 1. Molecular targets for therapy in systemic sclerosis.
    Iwamoto N; Distler O
    Fibrogenesis Tissue Repair; 2012; 5(Suppl 1):S19. PubMed ID: 23259845
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Innovative antifibrotic therapies in systemic sclerosis.
    Beyer C; Distler O; Distler JH
    Curr Opin Rheumatol; 2012 May; 24(3):274-80. PubMed ID: 22450392
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rationally-based therapeutic disease modification in systemic sclerosis: Novel strategies.
    Asano Y; Varga J
    Semin Cell Dev Biol; 2020 May; 101():146-160. PubMed ID: 31859147
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemic sclerosis and localized scleroderma--current concepts and novel targets for therapy.
    Distler O; Cozzio A
    Semin Immunopathol; 2016 Jan; 38(1):87-95. PubMed ID: 26577237
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanisms and consequences of fibrosis in systemic sclerosis.
    Denton CP; Black CM; Abraham DJ
    Nat Clin Pract Rheumatol; 2006 Mar; 2(3):134-44. PubMed ID: 16932673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evidence of an antifibrotic effect of immunosuppressive drugs: applications in the treatment of systemic sclerosis.
    Verrecchia F; Wang Y; Vija L; Farge D
    Expert Rev Clin Immunol; 2009 Jan; 5(1):35-43. PubMed ID: 20476898
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of agents for the treatment of systemic sclerosis.
    Herrick AL
    Expert Opin Investig Drugs; 2001 Jul; 10(7):1255-64. PubMed ID: 11772249
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interstitial Lung Disease in Systemic Sclerosis: Focus on Early Detection and Intervention.
    Fischer A; Patel NM; Volkmann ER
    Open Access Rheumatol; 2019; 11():283-307. PubMed ID: 31849543
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interstitial Lung Disease in Patients With Systemic Sclerosis: Toward Personalized-Medicine-Based Prediction and Drug Screening Models of Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD).
    Khedoe P; Marges E; Hiemstra P; Ninaber M; Geelhoed M
    Front Immunol; 2020; 11():1990. PubMed ID: 33013852
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical and translational research to discover potentially effective antifibrotic therapies in systemic sclerosis.
    Jordan S; Chung J; Distler O
    Curr Opin Rheumatol; 2013 Nov; 25(6):679-85. PubMed ID: 24047603
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Strategy for treatment of fibrosis in systemic sclerosis: Present and future.
    Yanaba K
    J Dermatol; 2016 Jan; 43(1):46-55. PubMed ID: 26782006
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent advances in the diagnosis and treatment of systemic sclerosis.
    Kowal-Bielecka O; Bielecki M; Kowal K
    Pol Arch Med Wewn; 2013; 123(1-2):51-8. PubMed ID: 23344666
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging targets of disease-modifying therapy for systemic sclerosis.
    Volkmann ER; Varga J
    Nat Rev Rheumatol; 2019 Apr; 15(4):208-224. PubMed ID: 30796362
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Treatment of systemic sclerosis-associated interstitial lung disease].
    Prasse A; Bonella F; Müller-Ladner U; Witte T; Hunzelmann N; Distler J
    Z Rheumatol; 2020 Apr; 79(3):294-303. PubMed ID: 31754786
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [B cell abnormalities and therapeutic strategies in systemic sclerosis].
    Yoshizaki A
    Nihon Rinsho Meneki Gakkai Kaishi; 2016; 39(3):197-206. PubMed ID: 27320935
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treating skin and lung fibrosis in systemic sclerosis: a future filled with promise?
    Antic M; Distler JH; Distler O
    Curr Opin Pharmacol; 2013 Jun; 13(3):455-62. PubMed ID: 23747024
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Do specific antifibrotic properties of immunosuppressive drugs used in the treatment of systemic sclerosis exist?].
    Verrecchia F; Michel L; Keshtmand H; Wang Y; Launay D; Farge D
    Rev Med Interne; 2009 Nov; 30(11):955-62. PubMed ID: 19349102
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phototherapy: a promising treatment option for skin sclerosis in scleroderma?
    Sunderkötter C; Kuhn A; Hunzelmann N; Beissert S
    Rheumatology (Oxford); 2006 Oct; 45 Suppl 3():iii52-iii54. PubMed ID: 16987838
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endothelin receptor antagonists as disease modifiers in systemic sclerosis.
    Shetty N; Derk CT
    Inflamm Allergy Drug Targets; 2011 Feb; 10(1):19-26. PubMed ID: 21184655
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting vascular disease in systemic sclerosis.
    Kowal-Bielecka O
    Endocr Metab Immune Disord Drug Targets; 2006 Dec; 6(4):401-7. PubMed ID: 17214586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.